These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone]. Parra-Ruiz J; Hernández-Quero J Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Thabit AK; Crandon JL; Nicolau DP Int J Antimicrob Agents; 2016 Nov; 48(5):535-541. PubMed ID: 27742208 [TBL] [Abstract][Full Text] [Related]
14. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Martin SJ; Jung R; Garvin CG Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723 [TBL] [Abstract][Full Text] [Related]
16. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. Drusano GL; Craig WA J Chemother; 1997 May; 9 Suppl 3():38-44. PubMed ID: 9248979 [TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Drusano G Clin Microbiol Infect; 2001; 7 Suppl 3():24-9. PubMed ID: 11523559 [TBL] [Abstract][Full Text] [Related]
19. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae. Appelbaum PC Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program. Jones RN; Pfaller MA Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]